Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636288 | 0.83 | MEN1 (0.39) | CNR1CNR2PPARDPPARAHTR2A | |
| SCHEMBL11348933 | 0.82 | HTR2A (0.47) | CNR1CNR2PPARDPPARAHTR2A | |
| SCHEMBL13639117 | 0.81 | TACR1 (0.37) | PPARDPPARAHTR2AMEN1HTT | |
| SCHEMBL13639096 | 0.81 | TACR1 (0.37) | PPARDPPARAHTR2AMEN1HTT | |
| SCHEMBL27935806 | 0.80 | HTR2A (0.41) | CNR1CNR2PPARDPPARAHTR2A | |
| SCHEMBL13639129 | 0.77 | HTR2A (0.43) | HTR2AMEN1KMT2A | |
| SCHEMBL13639088 | 0.77 | HTR2A (0.43) | HTR2AMEN1KMT2A | |
| SCHEMBL13636292 | 0.77 | MEN1 (0.40) | CNR1CNR2PPARDPPARAHTR2A | |
| SCHEMBL10961574 | 0.77 | GABRA1 (0.46) | PPARDPPARAHTR2AMEN1HTT | |
| SCHEMBL13639103 | 0.76 | TACR1 (0.36) | PPARDPPARAHTR2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | CNR1 2732/4885CNR2 3742/4885PPARD 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.